Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geranylgeranylacetone for HFpEF
NL-OMON53498Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in heart failure with preserved ejection fraction (HFpEF) comparing Teprenone with Placebo (2 arms). Primary endpoints: Change in left ventricular diastolic function and Change in endothelial function by reactive hyperemia index. Started Mar 2023; status: completed.
02
Drugs
teprenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON53498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53498.